Protocol Submitted to FDA for An Open-Label Feasibility and Safety Study of MDMA-Assisted Group Therapy for the Treatment of Posttraumatic Stress Disorder in Veterans (MPG1)

MAPS is sponsoring a Phase 2, open-label protocol to assess the feasibility and safety of MDMA-assisted group therapy for the treatment of PTSD in Veterans. The study will be conducted in up to 18 participants, recruited in three cohorts of six participants, who will receive therapy sessions throughout their participation in these groups at the Portland Veterans Affairs (VA) Medical Center in Oregon. The protocol was submitted to the FDA on November 8, 2021, and the study is anticipated to initiate in 2021.